- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04049045
Effects of Empagliflozin on Diuresis and Renal Function in Patients With Acute Decompensated Heart Failure (EMPAG-HF)
Heart failure is the most common hospital admission diagnosis and shows increasing incidence and prevalence in Germany, the United States and worldwide. Improvements in the primary treatment conditions for e.g. myocardial infarction and reduced primary mortality has resulted in an increasing group of patients with secondary cardiac abnormalities including chronic heart failure.
Progressive cardiac dysfunction and failure are associated with exercise intolerance, volume retention, nocturia, dyspnoea among others. The most severe progression of heart failure is cardiac decompensation (also called: acute heart failure) and cardiogenic shock. Volume retention, abnormal renal function and diuretic resistance are hallmarks of this clinical phenotype. Currently, the only available treatment is diuresis through various combinations of diuretics and the addition of cardiac inotropes when cardiac hypoperfusion is documented. Patients with acute decompensated heart failure (ADHF) often develop a state of diuretic resistance characterized by a need of rising dosages of diuretics for adequate diuresis and urine production.
ADHF patients also show metabolic abnormalities including insulin resistance or type 2 diabetes mellitus.
Empagliflozin is a potent and selective inhibitor of the sodium glucose cotransporter 2 (SGLT2) used in the treatment of type 2 diabetes. By inhibiting SGLT2, empagliflozin reduces renal glucose reabsorption and increases urinary glucose excretion. In addition to reducing hyperglycaemia, empagliflozin is associated with osmotic diuresis, reductions in weight and blood pressure without increases in heart rate, and has favourable effects on markers of arterial stiffness and vascular resistance.
The investigators propose a single center exploratory study to test the hypothesis that the application of empagliflozin in addition to standard diuretic regimens increases urine output, decreases the need for further acceleration of diuretic regimens, and positively influences renal function as well as metabolism including insulin resistance in ADHF patients. Thereby, empagliflozin may be effective in the prevention of complex cardio metabolic alterations involved in ADHF.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Jena, Germany, 07747
- Department of Internal Medicine I, Jena University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients (age between 18-85 years) with acute decompensated heart failure (HF).
- Brain Natriuretic Peptide (BNP) >100 pg/ml, or N-terminal pro-BNP (NT-proBNP)>300 pg/ml as defined by current clinical guidelines for the diagnosis of acute decompensated HF (European Society of Cardiology 2016 HF guideline)
- Patients with diabetes mellitus type 2 or impaired glucose tolerance as defined by current clinical guidelines (German and International Diabetes Society 2016: HbA1c>6.5 % (upper limit for this clinical trial 12 %) or fasting glucose >7.0 mmol/l or any incidental glucose level >11.1 mmol/l or abnormal oral glucose tolerance test with 2h plasma glucose >7.8 mmol/l) or on antidiabetic medication or antidiabetic diet or patients with normal Glucose tolerance
- Patients without cognitive impairment, i.e. they must be capable of understanding the nature, significance and implications of the clinical trial and to form a rational intention in the light of the facts
- Written informed consent obtained
For women with childbearing potential (until 2 years after menopause):
- Negative pregnancy test
- regular and correct use of a highly effective contraceptive method with an error rate of <1% per year (e.g. combined (estrogen and progesteron) hormonal contraception (oral, intravaginal, transdermal), progesteron-only hormonal contraception (oral, injectable, implantable), intrauterine device (IUD), intrauterine hormone-releasing system (IUS) tubal ligation (female sterilization), hormon donating intrauterine device ("hormonal spiral"), double barrier methods, sexual abstinence, vasectomy of the partner)
Exclusion Criteria:
- Type 1 diabetes mellitus
- Chronic Kidney Disease (CKD) with eGFR< 30 ml/min, or end-stage renal failure with the need for chronic dialysis treatment
- Acute kidney injury (AKI) ≥ Acute Kidney Injury Network (AKIN) stage 2 or requiring dialysis treatment
- Current medication with SGLT-2 inhibitors
- Known intolerance or hypersensitivity to the active substance empagliflozin, lactose or any other of the excipients listed in section 6.1. of the summary of product characteristics (SmPC). A contraindication or intolerance to furosemide
- Acute heart failure without signs of congestion ("dry" patient)
- Indication for urgent coronary angiography or any planned administration of a iodine based contrast agent within the next 6 days
- Need for hemofiltration or any other form of extracorporeal therapy
- Planned surgery
- Previous participation in this trial or recent participation in another clinical trial (within the last 3 months before inclusion, so that medical product/s from previous trial participation/s have been fully washed out )Identification of any causes of heart failure leading to decompensation that needs urgent management (like acute coronary syndrome, severe unstable arrhythmias, mechanical causes, acute pulmonary embolism)
- Incapacity to understand and / or to provide written informed consent
- Ongoing reported alcohol abuse (daily alcohol intake of more than 2 drinks (liquor, beer or wine) in men and 1 drink in women, corresponding to 12/24 g of pure alcohol per day women / men and/ or obvious alcoholisation of the patient during screening )
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Verum arm
25 mg tablet of empagliflozin once daily for five days
|
Empagliflozin 25 mg film-coated tablets, for oral use administered once daily for 5 days in addition to routinely administered (weight adjusted) intravenous furosemide
|
Placebo Comparator: Placebo arm
one tablet of the matching Placebo once daily for five days
|
matching Placebo, film-coated tablets, for oral use, matching to investigational product Jardiance® administered once daily for 5 days in addition to routinely administered (weight adjusted) intravenous furosemide
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Total urinary output (UOP) as measured by daily volume summed up over 5 days
Time Frame: 5 days
|
Total UOP as summed over 5 days
|
5 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Renal function under treatment
Time Frame: 5 days
|
Change of creatinine values: increase in creatinine of > 0.3 mg/dl, doubling of serum creatinine, need for renal replacement therapy
|
5 days
|
Net fluid output
Time Frame: 5 days
|
UOP - fluid intake
|
5 days
|
Worsening or persistent heart failure
Time Frame: 30 days
|
NYHA class (New York Heart Association functional heart failure classification)
|
30 days
|
Intermediate Care (IMC) / Intensive Care Unit (ICU) and hospital length of stay
Time Frame: 30 days
|
Duration in days
|
30 days
|
Liver function
Time Frame: 30 days
|
bilirubin, serum aminotransferases, relevant change in coagulation status
|
30 days
|
Pulmonary function
Time Frame: 30 days
|
oxygen saturation without oxygen therapy/ need for oxygen in l/min, presence of rales, changes in chest x-ray (worsening/ improvement/ new infiltration)
|
30 days
|
Number of patients alive and out of hospital -after 30 days
Time Frame: 30 days
|
number of patients
|
30 days
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety Outcome: Number of Adverse Events and Serious Adverse Events including MedDRA-SAE Preferred Terms and SOCs in both groups
Time Frame: 30 days
|
Listing of all adverse events and serious adverse events, laboratory parameters as far as not efficacy parameters
|
30 days
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Christian Schulze, Prof. Dr., Department of Internal Medicine I, Jena University Hospital
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ZKSJ0109
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Decompensated Heart Failure
-
Medical University of WarsawMedical University of Graz; Medical University of Vienna; Poznan University of... and other collaboratorsRecruitingAcute Decompensated Heart FailurePoland
-
Yooyoung Pharmaceutical Co., Ltd.RecruitingAcute Decompensated Heart FailureKorea, Republic of
-
Cardionomic Inc.Completed
-
Scripps HealthWithdrawnAcute Decompensated Heart FailureUnited States
-
Wake Forest University Health SciencesNational Institute on Aging (NIA)CompletedAcute Decompensated Heart FailureUnited States
-
Prof. Dr. Jörg LeuppiCompletedAcute Decompensated Heart FailureSwitzerland
-
Byung-Hee OhNational Institute of Health, KoreaCompletedAcute Decompensated Heart FailureKorea, Republic of
-
Trevena Inc.CompletedAcute Decompensated Heart FailureUnited States, Bulgaria, Poland, Russian Federation, Germany, Romania, Argentina, Canada, Czechia, Hungary, Israel, Slovakia
-
University of North Carolina, Chapel HillUniversity of Illinois at Chicago; Virginia Commonwealth UniversityTerminatedAcute Decompensated Heart FailureUnited States
-
Todd M Koelling, MDscPharmaceuticals, Inc.WithdrawnAcute Decompensated Heart FailureUnited States
Clinical Trials on Empagliflozin 25 mg
-
Instituto Nacional de Cardiologia Ignacio ChavezNot yet recruitingSTEMI | No-Reflow Phenomenon
-
National Taiwan University HospitalShin Kong Wu Ho-Su Memorial HospitalNot yet recruitingHeart Failure With Preserved Ejection Fraction | End Stage Renal Disease on Dialysis
-
University of Sao Paulo General HospitalRecruitingCoronary Artery Disease | Diabetes Mellitus, Type 2 | Acute Kidney Injury | Coronary Artery Bypass SurgeryBrazil
-
Boehringer IngelheimEli Lilly and CompanyCompletedDiabetes Mellitus, Type 2Japan
-
Amsterdam UMC, location VUmcCompleted
-
Yale UniversityBoehringer IngelheimRecruitingEnd Stage Renal Disease on DialysisUnited States
-
University Health Network, TorontoRecruiting
-
University of Mississippi Medical CenterEli Lilly and CompanyRecruiting
-
Tanta UniversityActive, not recruiting
-
Isfahan University of Medical SciencesCompletedDiabetes MellitusIran, Islamic Republic of